Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Nov;62(Suppl 2):ii55–ii59. doi: 10.1136/ard.62.suppl_2.ii55

B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience

T Shaw, J Quan, M Totoritis
PMCID: PMC1766758  PMID: 14532151

Full Text

The Full Text of this article is available as a PDF (208.0 KB).

Figure 1.

Figure 1

Open in a new tab

Potential roles of B cells in RA.

Figure 2.

Figure 2

Open in a new tab

Response to rituximab at six months in two independent studies each involving five patients with RA refractory to DMARD treatment treated (A) with or (B) without concomitant DMARD treatment.18,21

Figure 3.

Figure 3

Open in a new tab

ACR responses at six months in an interim cohort of patients with RA refractory to DMARD treatment treated with rituximab with and without concomitant cyclophosphamide or methotrexate, compared with continuation of methotrexate alone.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson D. R., Grillo-López A., Varns C., Chambers K. S., Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997 May;25(2):705–708. doi: 10.1042/bst0250705. [DOI] [PubMed] [Google Scholar]
  2. Clynes R. A., Towers T. L., Presta L. G., Ravetch J. V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000 Apr;6(4):443–446. doi: 10.1038/74704. [DOI] [PubMed] [Google Scholar]
  3. Czuczman M. S. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999 Oct;26(5 Suppl 14):88–96. [PubMed] [Google Scholar]
  4. De Vita Salvatore, Zaja Francesco, Sacco Stefania, De Candia Alessandro, Fanin Renato, Ferraccioli Gianfranco. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002 Aug;46(8):2029–2033. doi: 10.1002/art.10467. [DOI] [PubMed] [Google Scholar]
  5. Dörner Thomas, Burmester Gerd R. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol. 2003 May;15(3):246–252. doi: 10.1097/00002281-200305000-00011. [DOI] [PubMed] [Google Scholar]
  6. Edwards J. C. W., Leandro M. J., Cambridge G. B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders. Biochem Soc Trans. 2002 Aug;30(4):824–828. doi: 10.1042/bst0300824. [DOI] [PubMed] [Google Scholar]
  7. Edwards J. C., Cambridge G., Abrahams V. M. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999 Jun;97(2):188–196. doi: 10.1046/j.1365-2567.1999.00772.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edwards J. C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001 Feb;40(2):205–211. doi: 10.1093/rheumatology/40.2.205. [DOI] [PubMed] [Google Scholar]
  9. Gause A., Berek C. Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. BioDrugs. 2001;15(2):73–79. doi: 10.2165/00063030-200115020-00001. [DOI] [PubMed] [Google Scholar]
  10. Hainsworth John D., Litchy Sharlene, Burris Howard A., 3rd, Scullin Daniel C., Jr, Corso Steven W., Yardley Denise A., Morrissey Lisa, Greco F. Anthony. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002 Oct 15;20(20):4261–4267. doi: 10.1200/JCO.2002.08.674. [DOI] [PubMed] [Google Scholar]
  11. Leandro M. J., Edwards J. C. W., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002 Oct;61(10):883–888. doi: 10.1136/ard.61.10.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Leandro Maria J., Edwards Jonathan C., Cambridge Geraldine, Ehrenstein Michael R., Isenberg David A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 Oct;46(10):2673–2677. doi: 10.1002/art.10541. [DOI] [PubMed] [Google Scholar]
  13. Lipsky P. E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001 Sep;2(9):764–766. doi: 10.1038/ni0901-764. [DOI] [PubMed] [Google Scholar]
  14. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825–2833. doi: 10.1200/JCO.1998.16.8.2825. [DOI] [PubMed] [Google Scholar]
  15. McLaughlin P., Hagemeister F. B., Grillo-López A. J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999 Oct;26(5 Suppl 14):79–87. [PubMed] [Google Scholar]
  16. Panayi G. S. The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol. 1993 Mar;32 (Suppl 1):4–14. [PubMed] [Google Scholar]
  17. Pestronk A., Florence J., Miller T., Choksi R., Al-Lozi M. T., Levine T. D. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485–489. doi: 10.1136/jnnp.74.4.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Protheroe A., Edwards J. C., Simmons A., Maclennan K., Selby P. Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma. Rheumatology (Oxford) 1999 Nov;38(11):1150–1152. doi: 10.1093/rheumatology/38.11.1150. [DOI] [PubMed] [Google Scholar]
  19. Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994 Jan 15;83(2):435–445. [PubMed] [Google Scholar]
  20. Reparon-Schuijt C. C., van Esch W. J., van Kooten C., Ezendam N. P., Levarht E. W., Breedveld F. C., Verweij C. L. Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis. Arthritis Rheum. 2001 Sep;44(9):2029–2037. doi: 10.1002/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  21. Shiokawa Satoshi, Matsumato Naoyuki, Nishimura Junji. Clonal analysis of B cells in the synovial membrane of patients with rheumatoid arthritis. Scand J Rheumatol. 2003;32(1):12–18. doi: 10.1080/03009740310000346. [DOI] [PubMed] [Google Scholar]
  22. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952–957. doi: 10.1182/blood.v98.4.952. [DOI] [PubMed] [Google Scholar]
  23. Takemura S., Klimiuk P. A., Braun A., Goronzy J. J., Weyand C. M. T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001 Oct 15;167(8):4710–4718. doi: 10.4049/jimmunol.167.8.4710. [DOI] [PubMed] [Google Scholar]
  24. Zaja Francesco, De Vita Salvatore, Mazzaro Cesare, Sacco Stefania, Damiani Daniela, De Marchi Ginevra, Michelutti Angela, Baccarani Michele, Fanin Renato, Ferraccioli Gianfranco. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003 Jan 30;101(10):3827–3834. doi: 10.1182/blood-2002-09-2856. [DOI] [PubMed] [Google Scholar]
  25. Zhang Z., Bridges S. L., Jr Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. Rheum Dis Clin North Am. 2001 May;27(2):335–353. doi: 10.1016/s0889-857x(05)70205-2. [DOI] [PubMed] [Google Scholar]
  26. van Zeben D., Hazes J. M., Zwinderman A. H., Cats A., van der Voort E. A., Breedveld F. C. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis. 1992 Sep;51(9):1029–1035. doi: 10.1136/ard.51.9.1029. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES